SCHEMBL9924834

SCHEMBL9924834

CCCCC1CCC2CC(c3ccc(COc4ccc(OCC)c(F)c4F)cc3)CCC2C1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.34
RAB9A P51151 2/20 0.33
MAPT P10636 3/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
SPHK1 Q9NYA1 3/20 0.32
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
CRHBP P24387 1/20 0.32
HTT P42858 1/20 0.32
CRHR2 Q13324 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
HTR1A P08908 3/20 0.32
SLC6A2 P23975 3/20 0.32
SLC6A4 P31645 3/20 0.32
SLC6A3 Q01959 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9924835 0.97 SPHK1 (0.34) KDM1ARAB9AMAPTSMN1; SMN2KDM4E
SCHEMBL19188307 0.95 SPHK1 (0.34) KDM1ARAB9AMAPTSMN1; SMN2KDM4E
SCHEMBL9924833 0.94 KDM1A (0.35) KDM1ARAB9AMAPTSMN1; SMN2KDM4E
SCHEMBL12032168 0.93 KDM1A (0.36) KDM1ARAB9AMAPTSMN1; SMN2KDM4E
SCHEMBL9925161 0.93 SPHK1 (0.32) KDM1ARAB9AMAPTSMN1; SMN2KDM4E
SCHEMBL9925033 0.92 CYP2C9 (0.36) KDM1ARAB9AMAPTSMN1; SMN2KDM4E
SCHEMBL9924840 0.91 RAB9A (0.36) KDM1ARAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL9925107 0.91 KDM1A (0.33) KDM1ARAB9AMAPTSMN1; SMN2KDM4E
SCHEMBL9925075 0.91 MAPT (0.34) KDM1ARAB9AMAPTSMN1; SMN2KDM4E
SCHEMBL12032415 0.90 MAPT (0.35) KDM1ARAB9AMAPTSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8465674-B2 Decahydronaphthalene compound, liquid crystal composition including the compound and liquid crystal display device containing the liquid crystal composition JNC CORPORATION (JP) 2013-06-18 US disclosed
US-8465674-B2 Decahydronaphthalene compound, liquid crystal composition including the compound and liquid crystal display device containing the liquid crystal composition JNC CORPORATION (JP) 2013-06-18 US disclosed
US-20120145959-A1 DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION JNC PETROCHEMICAL CORPORATION (JP) 2012-06-14 US disclosed
US-20120145959-A1 DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION JNC PETROCHEMICAL CORPORATION (JP) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120145959-A1 DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION DCUN1D2, OCIAD1, CPNE4 KDM1A 1725/4885RAB9A 4571/4885MAPT 3409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.